Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment1.61%-0.77 ppPharmaceuticals4.10%+0.75 ppManaged Health Care0.93%+0.23 ppBiotechnology1.89%+0.10 ppHealth Care Technology0.08%+0.06 ppHealth Care Services0.48%+0.05 ppLife Sciences Tools & Services0.90%-0.03 ppHealth Care Facilities0.16%-0.02 ppHealth Care Supplies0.09%+0.00 ppHealth Care Distributors0.40%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
1.89%
Industry change · 12M
+0.10 pp
Biotechnology · contribution
+0.104 pp
Company participation
100%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Jul 2026 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $443.4bn | 0.774% | +0.267 pp | +0.070 pp | +36.9% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $121.1bn | 0.211% | +0.064 pp | -0.036 pp | +4.4% | Yes |
| Amgen → AMGN | United States | $207.9bn | 0.363% | +0.110 pp | +0.028 pp | +34.4% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $71.7bn | 0.125% | +0.035 pp | +0.017 pp | +40.6% | Yes |
| Moderna → MRNA | United States | $21.9bn | 0.038% | +0.014 pp | +0.014 pp | +85.5% | Yes |
| Biogen → BIIB | United States | $30.0bn | 0.052% | +0.014 pp | +0.013 pp | +58.6% | Yes |
| Gilead Sciences → GILD | United States | $161.7bn | 0.282% | +0.062 pp | -0.012 pp | +19.0% | Yes |
| Incyte → INCY | United States | $23.9bn | 0.042% | +0.016 pp | +0.011 pp | +59.6% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.